| Literature DB >> 24744814 |
Kathrin H Beckmann1, Gesa Meyer-Hamme1, Sven Schröder1.
Abstract
Diabetic foot ulcers as one of the most common complications of diabetes mellitus are defined as nonhealing or long-lasting chronic skin ulcers in diabetic patients. Multidisciplinary care for the diabetic foot is common, but treatment results are often unsatisfactory. Low level laser therapy (LLLT) on wound areas as well as on acupuncture points, as a noninvasive, pain-free method with minor side effects, has been considered as a possible treatment option for the diabetic foot syndrome. A systematic literature review identified 1764 articles on this topic. Finally, we adopted 22 eligible references; 8 of them were cell studies, 6 were animal studies, and 8 were clinical trials. Cell studies and animal studies gave evidence of cellular migration, viability, and proliferation of fibroblast cells, quicker reepithelization and reformed connective tissue, enhancement of microcirculation, and anti-inflammatory effects by inhibition of prostaglandine, interleukin, and cytokine as well as direct antibacterial effects by induction of reactive oxygen species (ROS). The transferral of these data into clinical medicine is under debate. The majority of clinical studies show a potential benefit of LLLT in wound healing of diabetic ulcers. But there are a lot of aspects in these studies limiting final evidence about the actual output of this kind of treatment method. In summary, all studies give enough evidence to continue research on laser therapy for diabetic ulcers, but clinical trials using human models do not provide sufficient evidence to establish the usefulness of LLLT as an effective tool in wound care regimes at present. Further well designed research trials are required to determine the true value of LLLT in routine wound care.Entities:
Year: 2014 PMID: 24744814 PMCID: PMC3976827 DOI: 10.1155/2014/626127
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Compilation of the Wagner and the Armstrong Ulcer Grade Classification System [5, 6].
| Wagner 0 | Wagner 1 | Wagner 2 | Wagner 3 | Wagner 4 | Wagner 5 | |
|---|---|---|---|---|---|---|
| Armstrong A | Pre- or postulcerative lesions | Superficial ulcer | Penetration to tendon, joint capsule | Penetration to bone, joint | Gangrene of digit | Gangrene of foot requiring disarticulation |
| Armstrong B | With infection | With infection | With infection | With infection | With infection | With infection |
| Armstrong C | With ischemia | With ischemia | With ischemia | With ischemia | With ischemia | With ischemia |
| Armstrong D | With ischemia and infection | With ischemia and infection | With ischemia and infection | With ischemia and infection | With ischemia and infection | With ischemia and infection |
Clinical trials on leg ulcer treatment with LLLT in diabetic ulcers.
| Study | Study design | Participants | Intervention | Outcome measures | Treatment outcome |
|---|---|---|---|---|---|
|
Schindl et al., 1998 [ | Randomized, double-blinded, placebo- controlled trial | 30 diabetic subjects with foot ulcer/gangrene | Single treatment HeNe laser 632.8 nm, 30 J/cm2 , 50 min | Temperature | Increase of microcirculation due to athermic laser irradiation |
|
| |||||
| Schindl et al., 1999 [ | Case studies | 20 patients with diabetes ( | 30 mW helium neon laser 632.8 nm, 30 J/cm2, 3 times weekly, 16–24 weeks until wound closure | Necessary treatments until wound closure | Ulcers due to radio damage healed significantly faster than those caused by diabetes autoimmune vasculitis and required lower time than that in radiodermatitis (nonsignificant);wound size was a predicting parameter but not wound depth and prior treatment |
|
| |||||
| Saltmarche, 2008 [ | Prospective comparative clinical trial | 21 open wounds and 4 “at risk” closed areas, and chronic (> or =3 months) and acute (<3 months) ulcers due to pressure, venous insufficiency, and diabetes | 5 times per week in first week, 3 times a week for more 8 weeks, 785 nm | Reduction of size | 61.9% of open wounds had significant reduction of size, 42.8% had 100% closure, 14.3% had some improvement, and 23.8% had no change no significant difference between chronic and acute wounds |
|
| |||||
| Zhou et al., 2008 [ | Randomized, molecular-biological analysis | 60 patients with 84 chronic dermal ulcers in diabetes patients and others | Daily till healing Helium neon (HeNe) laser, 632.8 nm | Healing rate, immunohistochemical analysis: HSP70, HSF1 | Expression of HSF1, HSP70, and RNA levels of HSF1 and HSP70 in laser group was significantly higher |
|
| |||||
| Minatel et al., 2009 [ | Randomized, placebo-controlled, double-blinded trial | 14 patients with 23 chronic diabetic ulcers | Twice a week till healing, at most 90 days, 660 nm and 890 nm, 3 J/cm2, 30 sec/5 cm2 | Healing rate and granulation | Treatment group had more granulation (day 30: 56%) and faster healing (day 30: 79.2%), 58.3% healed fully (1 ulcer placebo group); 75% ulcer healed 90–100% day 90 (one ulcer placebo group) |
|
| |||||
| Kaviani et al., 2011 [ | Randomized, placebo-controlled, double-blinded trial | 23 patients, diabetic foot wounds for at least three months | 2 times a week for 2 weeks then every second day till healing, 685 nm, 10 J/cm2 200 sec | Reduction of ulcer size and healing time | Significant reduction of ulcer size of 58 ± 10.4% in laser group to 23.5 ± 14.1% two weeks after treatment; healing time of treatment group: 11 weeks, placebo: 14 weeks, but not significant |
|
| |||||
| Kajagar et al., 2012 [ | Randomized controlled trial | 68 patients with chronic diabetic foot ulcers, conventional care + LLLT ( | Daily treatment for 15 days, 2–4 J/cm2 Power, 60 mW Frequency, 5 kHz | Ulcer size | Significant reduction of percentage of ulcer area LLLT group |
|
| |||||
| Landau et al., 2011 [ | Randomized, placebo-controlled, double-blinded trial | 14 patients with diabetic ulcers, 2 patients with venous ulcers | Twice daily for 12 weeks broadband (400–800 nm) 43.2 J/cm2, 4 minutes | Healing rate Reduction of size Wound closure time | Treatment group Healing: 90%, reduction of size: 89%, mean/median Wound closure time: 7.14/11.16 weeks Placebo group Healing: 33%, reduction of size: 54%, mean/median Wound closure time: 11.5 weeks |